Results 261 to 270 of about 61,179 (292)

Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial

Arthritis & Rheumatology, 2021
To determine whether serum urate reduction with allopurinol lowers blood pressure (BP) in young adults and the mechanisms mediating this hypothesized effect.
A. Gaffo, D. Calhoun, E. Rahn, S. Oparil, Peng Li, T. Dudenbostel, D. Feig, D. Redden, P. Muntner, P. Foster, Stephanie Biggers-Clark, A. Mudano, S. Sattui, Michael B Saddekni, S. L. Bridges, K. Saag   +15 more
semanticscholar   +1 more source

Effectiveness of Allopurinol in Reducing Mortality: Time‐Related Biases in Observational Studies

Arthritis & Rheumatology, 2021
The treatment of gout with allopurinol is effective at reducing urate levels and the frequency of flares. Several observational studies have shown important reductions in mortality with allopurinol use, with wide variations in results.
S. Suissa, K. Suissa, M. Hudson
semanticscholar   +1 more source

Combination Treatment with Verinurad and Allopurinol in CKD

Journal of the American Society of Nephrology
Visual Abstract Key Points The SAPPHIRE trial was designed to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with allopurinol in patients with CKD.
Hiddo J. L. Heerspink, Austin G. Stack, R. Terkeltaub, N. Jongs, L. Inker, M. Bjursell, Noha Maklad, S. Perl, Olof Eklund, T. Rikte, C. Sjöström, V. Perkovic   +11 more
semanticscholar   +1 more source

Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual‐Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial

Arthritis & Rheumatology, 2019
To examine whether allopurinol dose escalation to achieve serum urate (SU) target can influence bone erosion or monosodium urate (MSU) crystal deposition, as measured by dual‐energy computed tomography (DECT) in patients with gout.
N. Dalbeth, K. Billington, A. Doyle, C. Frampton, P. Tan, O. Aati, Jordyn Allan, J. Drake, A. Horne, L. Stamp   +9 more
semanticscholar   +1 more source

Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data

Annals of the Rheumatic Diseases, 2020
Objective To assess the risk of hypersensitivity reactions (HSRs) with allopurinol and febuxostat in a population-based study. Methods We used the 5% Medicare beneficiary sample (≥65 years) from 2006 to 2012 to identify people with a newly filled ...
J. Singh, J. Cleveland
semanticscholar   +1 more source

Highly Acylated Anthocyanins from Purple Sweet Potato ( Ipomoea batatas L.) Alleviate Hyperuricemia and Kidney Inflammation in Hyperuricemic Mice: Possible Attenuation Effects on Allopurinol.

Journal of Agricultural and Food Chemistry, 2019
Allopurinol is the first-line medication for hyperuricemia treatment. However, severe drug-related adverse effects have often been reported among patients who received allopurinol administration. This study is aimed at evaluating the possible attenuation
Zi‐cheng Zhang, Qing Zhou, Yang Yang, Yu Wang, Jiu‐liang Zhang   +4 more
semanticscholar   +1 more source

Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐Analysis

Clinical pharmacology and therapy, 2019
The safety of newer xanthine oxidase inhibitor febuxostat compared to allopurinol remains unclear. To compare the risks of allopurinol hypersensitivity and febuxostat hypersensitivity and cardiovascular diseases (CVDs) in Asians, we conducted a ...
Chi-Hua Chen, Chun-Bing Chen, Chee-Jen Chang, Y. Lin, Chuang-Wei Wang, C. Chi, Chun-Wei Lu, Wei-Ti Chen, R. Pan, S. Su, L. Hsu, Ya-Ching Chang, Kuang-Hui Yu, Y. Wu, Ko-Ming Lin, S. Hung, Shih-Ming Chen, W. Chung   +17 more
semanticscholar   +1 more source

Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.

European Heart Journal, 2019
AIMS Gout is associated with a higher risk of atrial fibrillation (AF). Comparative effectiveness of allopurinol or febuxostat for reducing the AF risk is unknown, which was our study's main objective.
J. Singh, J. Cleveland
semanticscholar   +1 more source